ResultsIQ › Latest results › Sai Life Sciences Limited
Sai Life Sciences Limited Q2 FY27 results deck summary
NSE: SAILIFE · BSE: 544306
Results deck of 6 Nov 2026, summarised by AI from the filing.
Capex for the overall projection of ₹1,100 to 1,300 cr is on track, after ₹621 cr spent in H1 FY27.
Key takeaways
- Capex guidance Capex for the overall projection of ₹1,100 to 1,300 cr is on track, after ₹621 cr spent in H1 FY27.
- Integrated model A second large pharma relationship was converted into a strategic engagement, and the first end-to-end collaboration is expected to be fully functional in Q3.
- Pipeline One molecule was added to the late phase pipeline and one advanced from late phase to commercial.
Sai Life Sciences Limited Q2 FY27 results
As filed: Revenue ₹659 cr (+23% year on year), EBITDA ₹186 cr (+28% year on year), PAT ₹98.3 cr (+17% year on year), EBITDA margin 28.3% (+111 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹554 cr (+12% year on year), EBITDA ₹148 cr (+22% year on year), PAT ₹73.3 cr (+22% year on year), EBITDA margin 26.7% (+231 bps). Score 64 of 100, In line with trend. EBITDA margin rose 231 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter. Share price after the results: +12.1% in 29 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹602 cr (+4% year on year), EBITDA ₹177 cr (+12% year on year), PAT ₹104 cr (+18% year on year), EBITDA margin 29.3% (+225 bps). Score 53 of 100, In line with trend. EBITDA margin rose 225 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +9.5% in 29 days (Nifty 500: −0.1%).
- Q3 FY26: Revenue ₹556 cr (+26% year on year), EBITDA ₹188 cr (+57% year on year), PAT ₹100 cr (+86% year on year), EBITDA margin 33.8% (+649 bps). Score 92 of 100, Above trend. EBITDA margin rose 649 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +27.9% in 29 days (Nifty 500: −4.0%).
- Q2 FY26: Revenue ₹527 cr, EBITDA ₹140 cr, PAT ₹83.0 cr, EBITDA margin 26.6%. Not scored. No result for the same quarter last year. Share price after the results: −5.0% in 29 days (Nifty 500: +1.4%).
- Q1 FY26: Revenue ₹483 cr, EBITDA ₹113 cr, PAT ₹58.0 cr, EBITDA margin 23.4%. Not scored. No result for the same quarter last year. Share price after the results: +8.7% in 29 days (Nifty 500: +0.6%).
- Q4 FY25: Revenue ₹567 cr, EBITDA ₹153 cr, PAT ₹90.0 cr, EBITDA margin 27.0%. Not scored. No result for the same quarter last year. Share price after the results: +6.1% in 30 days (Nifty 500: +2.5%).
- Q3 FY25: Revenue ₹429 cr, EBITDA ₹112 cr, PAT ₹51.0 cr, EBITDA margin 26.1%. Not scored. No result for the same quarter last year.
Past price moves after results do not indicate future moves. Not a recommendation.
Sai Life Sciences Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (6 Nov 2026), Results deck (6 Nov 2026), Results press release (6 Nov 2026)
- Q1 FY27: Results deck (7 Aug 2026), Results press release (6 Aug 2026)
- Q4 FY26: Results deck (15 May 2026), Results press release (14 May 2026)
- Q3 FY26: Results deck (6 Feb 2026), Results press release (5 Feb 2026)
- Q2 FY26: Results deck (7 Nov 2025), Results press release (6 Nov 2025)
- Q1 FY26: Results deck (8 Aug 2025), Results press release (8 Aug 2025)
- Q4 FY25: Earnings call (14 May 2025), Results deck (14 May 2025), Results press release (14 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.